VolitionRX Ltd (VNRX)
VolitionRX Ltd operates in the Medical - Devices industry of the Healthcare sector, headquartered in Henderson, NV, US. The stock last traded at $0.67, down 6.18% on the session, giving a market capitalisation of $5.6M. On trailing twelve-month figures it carries a trailing P/E of -0.16, a net margin of -997.5%. Its beta of 1.14 implies it has historically moved more than the broad market.
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VolitionRX Ltd is most often compared with the following Healthcare names: